Iovance Biotherapeutics Inc expected to post a loss of 45 cents a share - Earnings Preview

Iovance Biotherapeutics

30/10/2023 11:16

* Iovance Biotherapeutics Inc  IOVA.OQ   IOVA.O  is expected
to show a rise in quarterly revenue when it reports  results 
    * The San Carlos California-based  company is expected to
report
revenue of $4.192 million, according to the mean estimate from
13 analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Iovance
Biotherapeutics
Inc is for a loss of 45 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 12 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Iovance
Biotherapeutics Inc is $20​, above​ its last closing price
of $3.50. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.82       -0.80      -0.47     Beat    41
 Mar. 31 2023  -0.77       -0.74      -0.50     Beat    32.9
 Dec. 31 2022  -0.63       -0.64      -0.64     Met     -0.4​
 Sep. 30 2022  -0.63       -0.64      -0.63     Beat    1.2
 ​​Jun.        -0.59       -0.61      -0.63     Missed  -3.9
 30 2022                                                
 Mar. 31 2022  -0.64       -0.64      -0.58     Beat    8.9​
 Dec. 31 2021  -0.56       -0.56      -0.63     Missed  -12.9
 Sep. 30 2021  -0.52       -0.53      -0.55     Missed  -4.1
 This summary was machine generated October 30 at 11:16 GMT.  All
figures in US dollars  unless otherwise stated